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Abstract
Background: Multiplex Ligation-Dependent Probe Amplification (MLPA) is an application that can be used for the
detection of multiple chromosomal aberrations in a single experiment. In one reaction, up to 50 different genomic
sequences can be analysed. For a reliable work-flow, tools are needed for administrative support, data
management, normalisation, visualisation, reporting and interpretation.
Results: Here, we developed a data management system, MLPAInter for MLPA interpretation, that is windows
executable and has a stand-alone database for monitoring and interpreting the MLPA data stream that is
generated from the experimental setup to analysis, quality control and visualisation. A statistical approach is
applied for the normalisation and analysis of large series of MLPA traces, making use of multiple control samples
and internal controls.
Conclusions: MLPAinter visualises MLPA data in plots with information about sample replicates, normalisation
settings, and sample characteristics. This integrated approach helps in the automated handling of large series of
MLPA data and guarantees a quick and streamlined dataflow from the beginning of an experiment to an
authorised report.
Background
In medical research, knowledge of chromosomal dele-
tions or amplifications is of great importance. For exam-
ple, it can help us better understand the genetic causes
of certain diseases and as a consequence, improve the
treatment and prognosis of individual patients. Classic
techniques for the detection of chromosomal abnormal-
ities include karyotyping, Southern blotting, Fluorescent
In Situ Hybridisation (FISH), CA-repeat analysis and
quantitative micro satellite analysis by real-time PCR
[1-4]. In recent years, high-throughput methods based
on BAC arrays, SNP arrays and related techniques have
gained prominence [5,6]. Although these are excellent
tools for whole genome analysis, these techniques are
laborious, time-consuming, difficult to implement,
expensive and generate large data sets. The management
and interpretation of such voluminous data is not a light
task. Multiplex Ligation-dependent Probe Amplification
(MLPA) [7] has been introduced as a relatively cheap
and fast method to perform quantitative chromosomal
analysis of up to about 50 genomic DNA or RNA
sequences, which is able to distinguish sequences differ-
ing in only one nucleotide. This technique fills the gap
between the methods that investigate a single locus and
the techniques that interrogate thousands of loci.
MLPA is a quick and cost effective approach to testing
for the presence of gene deletions or obtaining tumour
profiles on multiple loci in a single tube, which can
easily be applied in molecular pathology. Furthermore,
MLPA only requires small amounts of DNA. Moreover,
DNA obtained from formalin fixed paraffin embedded
material can be used. Currently, MLPA is used for the
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validation of array-based comparative genomic hybridi-
sation (array-CGH) and SNP arrays [7-12]. Other appli-
cations for MLPA include methylation status
determination, copy number analysis in segmentally
duplicated regions, expression profiling, and transgene
genotyping [13]. The principle of MLPA is that for each
locus, two DNA oligonucleotides (probes) must hybri-
dise to their complementary target sequences on the
template DNA for ligation to occur. Subsequently a
PCR reaction is performed on the ligated probes. After
PCR, an aliquot of the PCR product is combined with
an internal size marker and deionised formamide. The
sample is then injected into a capillary of an automated
sequencer, where after a 30 minutes run, the data are
subsequently collected for further analysis. Since, the
amount of ligated probes is dependent on the number
of specific primer binding sites, this method is suitable
for the detection of chromosomal deletions or amplifica-
tions [7]
The analysis, visualisation and data management of
hundreds of samples with many different probes per
reaction can be cumbersome. Like in many modern
techniques, the results of an MLPA analysis are deliv-
ered as lists of values that can be easily imported into
spreadsheet applications. Large collections of individual
spreadsheets are not the best way to collect and analyse
data, especially in an environment where a controlled
work flow has to be guaranteed. A database system
offers advantages such as the tracking of material used
in the tests and consistency in the handling of test
results. Some of the information that needs to be mana-
ged includes: the origin of normal and test samples, the
experimental setup, the identity of the probes, and the
quality settings. Normalisation has to be performed
within and between samples and results have to be
visualised and stored. Sophisticated tools are needed to
facilitate the reliable use of MLPA [7,9,14-16]. In this
paper, we present a statistical technique for the normali-
sation of MLPA data and the software component that
we have developed to make MLPA a simple, effective,
and attractive tool. Here we describe MLPAinter, for
MLPA interpretation, a system that stores results,
instrument settings and sample descriptions in a Micro-
soft Access database. A special front-end, written in the
Borland Delphi language, allows the user to interrogate
the database, normalise data and visualise results as heat
maps and specialised plots.
Implementation
MLPA probe kits are obtained from MRC-Holland
(Amsterdam, The Netherlands). All assays are per-
formed according to the manufacturers’ protocols on an
ABI DNA sequencer (Applied Bio Systems, Foster City,
CA, USA). MLPAinter was constructed using Delphi
2009 (Embarcadero, San Francisco, CA, USA) for the
GUI, and Microsoft Office Access 2003 (Microsoft, Seat-
tle, WA, USA) for the standalone database. The runtime
requirements for the application are Windows XP or
newer. Statistics used in MLPAinter as described below,
were validated in a series of oligodendroglial tumours as
previously described [9]. The source code and a step by
step protocol to use MLPAinter together with showcase
sample files and analysis tables can be obtained from
http://code.google.com/p/mlpainter/
Results
Data pre-processing
MLPAinter can not handle the raw electrophoresis sig-
nal and therefore requires that the MLPA amplification
product peaks have already been linked to the corre-
sponding MLPA probes of the used MLPA kit. After
electrophoresis, all MLPA sample trace files should be
pre-processed in standard software for basic analysis of
MLPA traces. Subsequently, the report files can be
imported. Here we used GeneMapper (Applied Bio Sys-
tems, Foster City, CA, USA) for MLPAinter, but the sys-
tem can also import data from the combination
Genescan Analysis and Genotyper software (Applied Bio
Systems, Foster City, CA, USA). Adaptations to other
software programs like Genemarker (Softgenetics, State
College, PA, USA) should be straightforward. A step-by-
step vignette for Genemapper settings can be found at
http://code.google.com/p/mlpainter/. Briefly, the product
lengths of the ligated probes are defined with an internal
size standard. The peak height and area are calculated
for every peak present in the trace. Any undefined peaks
are discarded from further analysis. Data tables are then
automatically generated with length, height and area of
all recognised peaks. These tables are exported from the
Genemapper software package and imported into
MLPAinter for specific analysis of the raw data. Proto-
cols for linking output files from other software
packages are planned for future versions.
Data management
Here, we developed a relational database using Micro-
soft Access to manage all pertinent information for
MLPA experiments and created a front end with Bor-
land Delphi to guide laboratory workflow and data ana-
lysis. Characteristics such as the sample number and
status, e.g., tumour or normal, DNA concentration and,
if available, tumour percentages that are relevant for the
performance of the MLPA should be stored in a data-
base. Annotation information like the chromosomal
position and gene names of the different probes in a kit
should be available for the interpretation of the results
in output tables, heat maps, and plots. To assist the
laboratory work-flow, electronic and paper sample
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sheets can be prepared for the automated sequencer.
The raw data of the sequencing reports are imported
into the database for subsequent quality control steps
and analysis.
The relational database contains three hierarchies
which are interconnected. The hierarchies are MLPA
kits and probes, electrophoresis results, and analyses. In
the database tables, next to the specific Kit information,
you can find gene and probe names, as well as the phy-
sical and cytogenetic location of the probes. All probes
in a particular kit are numbered from 1, for the probe
with the smallest product size to n, for the probe with
the largest product size. Every kit contains a number of
probes that can be used for a quality check of the trace.
The corresponding products are named based on their
size in base pairs. The different kits as defined by MRC-
Holland, can be imported from http://www.mlpa.com.
Both the MLPA run and analysis hierarchy use the
samples table. This table contains clinical information
like the origin of the used DNA, e.g., if the DNA is iso-
lated from whole blood, fresh frozen tissue or formalin
fixed paraffin embedded tissue. Every sample is labelled
with an N for Normal, T for Test or the Tumour origin
of the tissue. Normal samples are treated differently
from test samples in the normalisation and analysis
steps as described in the normalisation section. An elec-
trophoresis run typically consists of a sample plate to be
processed by the sequencer. The sample, the kit, and a
unique name for the plate are recorded for each position
on the sample plate. Different types of kits can be used
within one run. From this information a sample sheet or
configuration file is created for the sequencer. The
resulting peak heights and peak areas of an MLPA run
are imported for all of the probes in a kit and the analy-
sis settings can be set to analyse peak heights or peak
areas.
During analysis, specific MLPA runs can be combined
from one or more electrophoresis runs. A group of
reference probes can be copied from another analysis
with the same kit, and can be adapted to suit the needs
of the specific analysis. However, to avoid inter experi-
mental differences, values from experiments performed
at a different time should not be used. Probes can also
be excluded from the analysis. Successful analysis can be
finalised by authorising the results. After authorising the
analysis, all options are fixed except for visualisation and
sorting options.
Quality control
MLPAinter presents three data quality indicators, Q1,
Q2 and Q3, (Figure 1A) to assist with the decision of
whether to include a trace in the analysis.
The first indicator (Q1) is the ratio between the ligation
dependent peak at 94 base pairs and the median of the
DNA dependent 64, 70, 76 and 82 peaks (Figure 2). Van
Dijk et al. [10] state that this ratio should be greater than
5 to obtain good and reproducible results. Nonetheless,
we have observed that in some cases, lower ratios can
also give reliable peak patterns (Figure 2).
The second quality indicator (Q2) is the median peak
height of the probe signals present in the kit. If the
median of the first 20 ligated probe peak heights is
below 450 relative fluorescent units (RFU), the trace
quality is considered low. Moreover, because of the lim-
its in the detection optics of the instrument, a median
peak height over 4000 RFU is indicative that the trace
quality is low (Figure 2) [14].
For the last indicator (Q3) all analysis peaks are split
in 2 parts based on sequence length. The value is com-
puted as the median signal of the longest probes divided
by the median signal of the shortest probes. Often the
longest probes show lower signals, however in high
quality traces this indicator is usually over 0.5.
Other factors that are important for the assessment
of quality, which can optionally be stored into the
database, are the DNA concentration of the sample,
the tumour percentage of the tumour specimens and
the intrinsic DNA quality of the sample. The combina-
tion of these quality parameters allows the user to
decide on inclusion or exclusion of a trace from the
analysis.
Normalisation
Raw MLPA results are not calibrated. Peak areas or
heights are dependent on sample quality, hybridisation
parameters and instrument settings. To analyse the
MLPA traces, internal and external control loci are used
for the normalisation of the data. External controls, e.g.,
normal tissue in tumour analysis, have to be present in
every experiment for the pattern comparison. Internal
controls for the calibration of the samples are present in
every kit and are supposed to be non-altered or refer-
ence probes in a tumour sample. These reference probes
are compared to the probes where DNA changes are
expected.
The top trace in Figure 2 shows a normal sample. It is
evident that peak heights or areas differ between probes;
and these differences have to be corrected. Also the
average peak areas or heights may differ from sample to
sample. Therefore, sample calibration and probe calibra-
tion have to be performed. Consider the data as a
matrix Y, with columns for the probes and rows for the
sample. Then, we need to apply normalisation to both
rows and columns. Normalisation is implemented as
division by row parameters ri, i = 1 ... m and column
parameters cj, j = 1 ... n, such that a matrix X = [xjj]
results, with xjb = yjb/(ricj). We prefer to work on the
original scale instead of with logarithms because loss
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Figure 1 MLPAinter for MLPA interpretation. Panel A: Heat map of an authorised series of samples after normalisation. The probes are sorted
by the name of the gene. The gain and loss columns show the total number of probes with gain or loss. Q1-3 show the different quality scores
calculated from the DNA dependent probes (marked 101-104) and the ligation dependent probe (105) and as explained in the text. Dark grey
cells: calibration probes, the id has a suffix ‘c’. Light grey cells: reference probes, the id has a suffix ‘r’. Yellow cells: probes with loss of one allele
(< 0.8). Blue cells: probes with gain of one allele (>1.25). Panel B: Sample plot of an individual sample after normalisation. The quality indices for
each replicate are shown. Replicates are visualised in different colours. Probes are sorted by the gene name combined with the chromosomal
position. The standard scale can be adjusted in case of samples with amplified probes (see panel C).
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and gain correspond to integer ratios (including zero)
on the original scale.
A simple approach would be to take row and column
medians for r and c, respectively. This could work well if
the number of deletions or amplifications is relatively
small. However, for samples with a large number of
deletions (more than 50%), the corresponding row med-
ian might become a number near zero and normalisa-
tion by dividing with this small number would give a
completely wrong result.
To improve normalisation and obtain calibration fac-
tors, we use only a subset of the samples and probes.
Specifically, we use normal samples, and only a subset
of the probes, where copy number changes are unlikely,
even in tumour samples. We use the following algo-
rithm:
1. To correct for the sample-to-sample variation,
divide the peak heights or areas of all the probes in
each sample by their median. This gives provisional
row parameters, ř for the normal samples, and pro-
visional normalisation of the normal samples.
2. To correct for systematic differences between
probes, divide the peak heights or areas of all the
probes within a MLPA run by their median. This
results in the normalised peak areas or heights, and
represents the column parameters c for all probes.
The average of all probes is now close to 1.
3. Select the probes that have a small probability of
change in copy number. Call these the reference
probes. The remaining probes are called the focus
probes, since we look for changes in these. The
description file for commercial kits includes this
information, and the program uses these probes by
default.
4. Select the part of the data that represents the nor-
mal control or non-tumour samples and the refer-
ence probes.
5. Redo steps 1 and 2 for the subsets of reference
samples and reference probes.
6. Determine which probes are most stable. Subtract
1 from each normalised peak height or area and take
the absolute value. Compute for integrated MLPA
analysis the median of these numbers for each
probe. This is the median of the absolute deviations:
MAD.
7. The reference probes with the lowest MAD are
most stable. Select the five probes closest to zero.
These are the probes that we call the calibration
probes.
8. Compute the median peak height or area of the 5
calibration probes for each sample (normal and test
samples or tumours and non-tumours). Divide all
peak heights or areas as computed in step 2 in each
sample by this value. This gives the final row para-
meters r for all samples, and their final
normalisation.
Reference probe selection
As in quantitative RT-PCR, the selection of reference
probes is a critical element of the analysis [17]. MLPA
kits contain about 10 reference probes that are includ
for normalisation purposes because they are not
involved in the experimental hypothesis/diagnostic ques-
tion. Alternatively, one can usually find a subset of
Figure 2 MLPA sample trace files. Overview of 5 different sample traces obtained with MLPA kit P105 (Oligodendroglioma-2) showing the
necessity of data normalisation. Differences in and between samples are hard to distinguish. Quality aspects of every trace are visible. Probe
lengths in base pairs are shown on the x-axis. Box 1: four no template control peaks of 64, 70, 76 and 82 bases, respectively. Box 2: a 94 base
pair ligation control peak. Box 3 and 4: larger peaks in the first half than in the second half of the sample trace. Box 5: peak heights are noted
on the y-axis
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probes in existing kits that are known not to be involved
in the hypothesis. The procedure selects the most stable
probes from the reference probes to calibrate the data.
The number of calibration probes used (five, in this
instance) did not significantly influence the results (data
not shown). However, the number is configurable in the
program. If probes show high variability between repli-
cates or between normal samples, they should be
excluded from the analysis.
Visualisation
We have designed a number of visualisations to inter-
pret the results after the normalisation and quality con-
trol of the data set. The first visualisation is a heat map
that shows all of the data in an experiment. Deletions
and gains are colour-coded with configurable thresholds.
Probes can be sorted by locus names or chromosomal
position. The reference and calibration probes are
clearly differentiated by a grey-shade (Figure 1). Another
visualisation shows the normalised values of all repli-
cates of one sample in a plot (Figure 1). Technical repli-
cates are shown in different colours. On the x-axis, the
different probes are shown in the selected probe order.
The y-axis is on a scale from 0 to 2.5, where 0 stands
for absent probes. Ideally probes at genomic loci with
loss of a single allele show values around 0.5. Unaltered
probes are visualised around 1.0. Probes with DNA
gains have values around 1.5 or above. In tumour sam-
ples contaminated with normal DNA these values are
usually not that outspoken. The researcher should keep
this in mind during the interpretation. Information
about sample characteristics and probes used are also
shown in the plots.
Future developments
Currently the system is suited for the analysis, visualisa-
tion and data management of MLPA. However, all of
the information generated during an experiment is still
not fully integrated in the data analysis. For instance,
tumour percentages can be stored in the database and
will be displayed, but it is up to the user to incorporate
this information into the interpretation. We plan to
include the tumour percentage and probably the DNA
index for automated identification of the allelic state of
the chromosomal aberrations in the analysed sample
[18]. Another worthwhile improvement would be to
remove the dependency on an external program to do
the peak detection.
Discussion
MLPA has a variety of applications for the detection of
changes in dosage at a single locus, e.g., a subtelomeric
locus, to those with multiple changes. Up to 50 different
probes (genomic sequences) can be interrogated in one
single reaction. Advantages are that only small amounts
of DNA are needed and that DNA isolated from forma-
lin fixed paraffin embedded material can be used. As it
stands, currently available software tools for MLPA ana-
lysis do not integrate data management, normalisation
and visualisation, and do not always perform adequate
data normalisation between and within traces. In these
packages, the quality aspects of the analysis are not
always taken into consideration. Therefore, we have
developed a method for MLPA data interpreting,
MLPAinter, in which sample information can be stored,
and where the laboratory and analysis workflow is
assisted. Experiments are prepared by selecting samples
and MLPA kits. Then sample sheets for automated
sequencers are generated, which can easily be imported
in the sequencer, avoiding manual input and typing
errors. Analysis tables can then be imported from stan-
dard DNA analysis programs. Given the sensitivity and
reproducibility of this methodology, the requirements
for proper internal controls for normalisation have to be
stringent [17]. For that reason, in each kit, the manufac-
turer has provided sets of reference probes for sample
data. However, for the analysis of unpredictable
(tumour) samples, these provided reference probes may
be inadequate. Thus, we created an algorithm that will
select the 5 most stable reference probes and suggest
that these probes be used for the normalisation of the
traces. The user has full control over the settings of the
analysis, and changes like including or excluding sam-
ples or designating probes as reference probes result in
immediate recalculations. All calculations can be visua-
lised in plots. By authorising the results, the analysis set-
tings are definitively linked to the analysis and can no
longer be changed.
MLPA results are, in general, very reproducible. Still,
we perform all tests at least in duplicate, especially in a
diagnostic setting. MLPAinter supports the handling of
replicates in the analysis. We previously validated the sta-
tistics used for MLPAinter on a series of DNAs that were
obtained from formalin fixed and paraffin embedded oli-
godendroglial tumours by correlating the results with
those obtained by fluorescent in situ hybridisation
(FISH). The MLPA results were reproducible in all sam-
ples in which repeated experiments were performed [9].
Conclusions
We have combined the analysis, visualisation and data
management for MLPA in a tool, MLPAinter for MLPA
interpretation, which makes use of a relational database
with a Delphi front end. This integrated approach helps
in the automated handling of large series of MLPA data
and helps to guarantee a quick and streamlined dataflow
from the initiation of an experiment to the generation
of authorised report. MLPAinter has been successfully
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used in our lab for over two years to manage over 3000
samples. Moreover, different MLPA kits have been suc-
cessfully used for this type of analysis, e.g., Kit P088 and
P105 for the analysis of Oligodendrogliomas, P024 for
CDKN2A/B and P036 for subtelomeric regions.
Availiability and Requirements
Project name: MLPAinter
Project home page: http://code.google.com/p/mlpainter/
Operating system(s): Windows XP or higher
Programming language: Delphi
Other requirements: no
Licence: GNU GPL 3.0
Any restrictions to use by non-academics: no
Abbreviations
MLPA: Multiplex Legation-Dependent Probe Amplification; RFU: relative
fluorescent units; RT-PCR: Real Time-PCR; MAD: median of the absolute
deviations.
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